The researchers found that fewer children with mothers being prescribed sodium valproate during pregnancy achieved the national minimum standard in the core subject indictor (CSI), mathematics, language, and science.
By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.
The percentage of children who have ever had a significant head injury also increased as age increased, peaking at 11.7% among 15-to-17-year-old children.
Embrace uses advanced machine learning to monitor for grand mal or generalized tonic-clonic seizures, and sends an alert to summon caregivers' help.
After a pregnancy with eclampsia, a future seizure disorder was significantly more likely (4.58/10,000 person-years) compared with a pregnancy without a hypertensive disorder of pregnancy (0.72/10,000 person-years; crude hazard ratio [HR], 6.09).
Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.
The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.
Results from the analysis showed the odds of Brineura-treated patients not having a decline were 13 times the odds of natural history cohort patients not having a decline (odds ratio 13.1, 95% CI: 1.2, 146.9).
Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.
Overall, the researchers found no variation in tolerability or adherence to the 3 medications based on gender, race, education or age.
Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
Carnexiv, an antiepileptic drug, is a short-term (≤7 days) intravenous (IV) replacement therapy for oral carbamazepine formulations in adults.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for edaravone (MCI-186; Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis (ALS).
A new meta-analysis found no evidence to suggest levetiracetam treatment is superior to phenytoin for early or late seizure prophylaxis in patients experiencing seizures following traumatic brain injuries (TBI)
A genetic test may one day be able to predict the risk for Alzheimer's disease (AD) in young adults, according to a study published online July 6 in Neurology.
A 28-week open-label study of the adjunct antiepileptic drug, lacosamide, showed that it had a low risk of adverse mood effects and a low risk for overall effect on cognition.
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Sabril (vigabatrin; Lundbeck) tablets, meaning prescribers will no longer be required to submit an ophthalmologic assessment form (OAFs) as part of the risk evaluation and mitigation strategy (REMS).
Mitsubishi Tanabe Pharma announced that a New Drug Application has been submitted to the Food and Drug Administration (FDA) for edaravone (MCI-186) for the treatment of amyotrophic lateral sclerosis (ALS).
Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures.
Eisai announced the availability of Fycompa (perampanel) Oral Suspension for use in patients who have difficulty swallowing tablets or prefer liquids.
ANI announced that the Food and Drug Administration (FDA) has approved Oxcarbazepine Tablets, the generic version of Novartis' Trileptal. In addition, ANI announced the launch of Oxycodone HCl Capsules.
Many newly infected HIV patients experience neurological symptoms, but they tend to be mild and subside after initiation of antiretroviral treatment.
Teva announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of SD-809 (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD).
Upsher-Smith announced that the FDA has granted tentative approval for a supplemental New Drug Application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use in adults as prophylaxis of migraine headache.
An investigational multiple sclerosis (MS) treatment demonstrated the ability to stop relapses and new brain lesion development for a prolonged period without the need for ongoing medication, in a new phase 2 clinical trial.